Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Protein-Protein Interaction.

Heightman TD, Callahan JF, Chiarparin E, Coyle JE, Griffiths-Jones C, Lakdawala AS, McMenamin R, Mortenson PN, Norton D, Peakman TM, Rich SJ, Richardson C, Rumsey WL, Sanchez Y, Saxty G, Willems HMG, Wolfe L 3rd, Woolford AJ, Wu Z, Yan H, Kerns JK, Davies TG.

J Med Chem. 2019 May 9;62(9):4683-4702. doi: 10.1021/acs.jmedchem.9b00279. Epub 2019 Apr 25.

PMID:
30973731
2.

Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo.

Boehm J, Davis R, Murar CE, Li T, McCleland B, Dong S, Yan H, Kerns J, Moody CJ, Wilson AJ, Graves AP, Mentzer M, Qi H, Yonchuk J, Kou JP, Foley J, Sanchez Y, Podolin PL, Bolognese B, Booth-Genthe C, Galop M, Wolfe L, Carr R, Callahan JF.

Bioorg Med Chem. 2019 Feb 15;27(4):579-588. doi: 10.1016/j.bmc.2018.12.026. Epub 2018 Dec 21.

PMID:
30626555
3.

Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress.

Yonchuk JG, Foley JP, Bolognese BJ, Logan G, Wixted WE, Kou JP, Chalupowicz DG, Feldser HG, Sanchez Y, Nie H, Callahan JF, Kerns JK, Podolin PL.

J Pharmacol Exp Ther. 2017 Oct;363(1):114-125. doi: 10.1124/jpet.117.241794. Epub 2017 Aug 8.

PMID:
28790194
4.

Discovering Drugs with DNA-Encoded Library Technology: From Concept to Clinic with an Inhibitor of Soluble Epoxide Hydrolase.

Belyanskaya SL, Ding Y, Callahan JF, Lazaar AL, Israel DI.

Chembiochem. 2017 May 4;18(9):837-842. doi: 10.1002/cbic.201700014. Epub 2017 Mar 24.

PMID:
28281333
5.

Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.

Davies TG, Wixted WE, Coyle JE, Griffiths-Jones C, Hearn K, McMenamin R, Norton D, Rich SJ, Richardson C, Saxty G, Willems HM, Woolford AJ, Cottom JE, Kou JP, Yonchuk JG, Feldser HG, Sanchez Y, Foley JP, Bolognese BJ, Logan G, Podolin PL, Yan H, Callahan JF, Heightman TD, Kerns JK.

J Med Chem. 2016 Apr 28;59(8):3991-4006. doi: 10.1021/acs.jmedchem.6b00228. Epub 2016 Apr 12.

PMID:
27031670
6.

Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO.

Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, Callahan JF, Carr R, Concha N, Kerns JK, Qi H, Sweitzer T, Ward P, Davies TG.

PLoS One. 2014 Jun 4;9(6):e98896. doi: 10.1371/journal.pone.0098896. eCollection 2014.

7.

Analytical approaches for quantification of a Nrf2 pathway activator: overcoming bioanalytical challenges to support a toxicity study.

Perez HL, Junnotula V, Knecht D, Nie H, Sanchez Y, Boehm JC, Booth-Genthe C, Yan H, Davis R, Callahan JF.

Analyst. 2014 Apr 21;139(8):1902-12. doi: 10.1039/c3an02216a.

PMID:
24563904
8.

Keap calm, and carry on covalently.

Wilson AJ, Kerns JK, Callahan JF, Moody CJ.

J Med Chem. 2013 Oct 10;56(19):7463-76. doi: 10.1021/jm400224q. Epub 2013 Jul 25.

PMID:
23837912
9.

In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.

Podolin PL, Bolognese BJ, Foley JF, Long E 3rd, Peck B, Umbrecht S, Zhang X, Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M, Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP Jr, Kurali E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF.

Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. doi: 10.1016/j.prostaglandins.2013.02.001. Epub 2013 Feb 19.

PMID:
23434473
10.

Development of a semi-automated LC/MS/MS method for the simultaneous quantitation of 14,15-epoxyeicosatrienoic acid, 14,15-dihydroxyeicosatrienoic acid, leukotoxin and leukotoxin diol in human plasma as biomarkers of soluble epoxide hydrolase activity in vivo.

Zhu P, Peck B, Licea-Perez H, Callahan JF, Booth-Genthe C.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2487-93. doi: 10.1016/j.jchromb.2011.06.042. Epub 2011 Jul 6.

PMID:
21798825
11.

Specialized training on addictions for physicians in the United States.

Tontchev GV, Housel TR, Callahan JF, Kunz KB, Miller MM, Blondell RD.

Subst Abus. 2011 Apr;32(2):84-92. doi: 10.1080/08897077.2011.555702.

12.

Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.

Marquis RW, Lago AM, Callahan JF, Rahman A, Dong X, Stroup GB, Hoffman S, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Roethke T, Smith BR, Ward KW, Bhatnagar P.

J Med Chem. 2009 Nov 12;52(21):6599-605. doi: 10.1021/jm900563e.

PMID:
19821575
13.

An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.

Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup GB, Vaden VR, Haley H, Fox J, DelMar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA.

Bone. 2010 Feb;46(2):534-42. doi: 10.1016/j.bone.2009.09.028. Epub 2009 Sep 26.

PMID:
19786130
14.

Progress towards the development of anti-inflammatory inhibitors of IKKbeta.

Bamborough P, Callahan JF, Christopher JA, Kerns JK, Liddle J, Miller DD, Morse MA, Rumsey WL, Williamson R.

Curr Top Med Chem. 2009;9(7):623-39. Review.

PMID:
19689370
15.

Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.

Marquis RW, Lago AM, Callahan JF, Trout RE, Gowen M, DelMar EG, Van Wagenen BC, Logan S, Shimizu S, Fox J, Nemeth EF, Yang Z, Roethke T, Smith BR, Ward KW, Lee J, Keenan RM, Bhatnagar P.

J Med Chem. 2009 Jul 9;52(13):3982-93. doi: 10.1021/jm900364m.

PMID:
19492813
17.

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS.

Mol Pharmacol. 2002 Jul;62(1):65-74.

PMID:
12065756
18.

Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA.

Mol Pharmacol. 2002 Jul;62(1):58-64.

PMID:
12065755
19.

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease.

Roshak AK, Callahan JF, Blake SM.

Curr Opin Pharmacol. 2002 Jun;2(3):316-21. Review.

PMID:
12020477
20.

Inhibition of hematopoietic progenitor cell growth by Tyr-MIF, an endogenous opiate modulator, and its degradation products.

Horowitz D, Callahan JF, Pelus LM, Fukuda S, King AG.

Int Immunopharmacol. 2002 Apr;2(5):721-30.

PMID:
12013510
21.

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ.

J Med Chem. 2002 Feb 28;45(5):999-1001.

PMID:
11855979
22.

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J.

J Clin Invest. 2000 Jun;105(11):1595-604.

23.

Novel peptidomimetic hematoregulatory compounds.

Heerding DA, Abruzzese M, Alberts D, Burgess J, Callahan JF, Huffman WF, King AG, LoCastro S, DeMarsh P, Pelus LM, Takata JS, Bhatnagar PK.

Bioorg Med Chem Lett. 2000 Mar 20;10(6):531-4.

PMID:
10741547
24.

Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

J Med Chem. 2000 Jan 13;43(1):22-6. No abstract available.

PMID:
10633035
25.

Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.

Keenan RM, Callahan JF, Samanen JM, Bondinell WE, Calvo RR, Chen L, DeBrosse C, Eggleston DS, Haltiwanger RC, Hwang SM, Jakas DR, Ku TW, Miller WH, Newlander KA, Nichols A, Parker MF, Southhall LS, Uzinskas I, Vasko-Moser JA, Venslavsky JW, Wong AS, Huffman WF.

J Med Chem. 1999 Feb 25;42(4):545-59.

PMID:
10052962
26.

Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonists.

Keenan RM, Miller WH, Lago MA, Ali FE, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Hwang SM, Jakas DR, Ku TW, Kwon C, Nguyen TT, Reader VA, Rieman DJ, Ross ST, Takata DT, Uzinskas IN, Yuan CC, Smith BR.

Bioorg Med Chem Lett. 1998 Nov 17;8(22):3165-70.

PMID:
9873696
27.

Reviewing ASAM's goals and accomplishments. American Society of Addiction Medicine.

Callahan JF.

J Addict Dis. 1998;17(2):123-8. No abstract available.

PMID:
9567229
28.

Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.

Keenan RM, Miller WH, Kwon C, Ali FE, Callahan JF, Calvo RR, Hwang SM, Kopple KD, Peishoff CE, Samanen JM, Wong AS, Yuan CK, Huffman WF.

J Med Chem. 1997 Jul 18;40(15):2289-92. No abstract available.

PMID:
9240343
29.

Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.

Samanen JM, Ali FE, Barton LS, Bondinell WE, Burgess JL, Callahan JF, Calvo RR, Chen W, Chen L, Erhard K, Feuerstein G, Heys R, Hwang SM, Jakas DR, Keenan RM, Ku TW, Kwon C, Lee CP, Miller WH, Newlander KA, Nichols A, Parker M, Peishoff CE, Rhodes G, Ross S, Shu A, Simpson R, Takata D, Yellin TO, Uzsinskas I, Venslavsky JW, Yuan CK, Huffman WF.

J Med Chem. 1996 Dec 6;39(25):4867-70. No abstract available.

PMID:
8960544
30.

Structure-activity relationships of novel hematoregulatory peptides.

Bhatnagar PK, Agner EK, Alberts D, Arbo BE, Callahan JF, Cuthbertson AS, Engelsen SJ, Fjerdingstad H, Hartmann M, Heerding D, Hiebl J, Huffman WF, Hysben M, King AG, Kremminger P, Kwon C, LoCastro S, Løvhaug D, Pelus LM, Petteway S, Takata JS.

J Med Chem. 1996 Sep 13;39(19):3814-9.

PMID:
8809169
31.

A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.

Hoog SS, Zhao B, Winborne E, Fisher S, Green DW, DesJarlais RL, Newlander KA, Callahan JF, Moore ML, Huffman WF, et al.

J Med Chem. 1995 Aug 18;38(17):3246-52.

PMID:
7650677
32.

Addiction medicine: definition of the specialty through definition of the practice.

Callahan JF.

J Addict Dis. 1995;14(2):101-7. No abstract available.

PMID:
8541355
33.

Conformational study of eight-membered diazocine turn mimics by two-dimensional NMR spectroscopy.

Bean JW, Briand J, Burgess JL, Callahan JF.

FEBS Lett. 1994 Nov 7;354(2):143-8.

34.

A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.

Newlander KA, Callahan JF, Moore ML, Tomaszek TA Jr, Huffman WF.

J Med Chem. 1993 Aug 6;36(16):2321-31.

PMID:
8360876
35.

Design and synthesis of a C7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists.

Callahan JF, Bean JW, Burgess JL, Eggleston DS, Hwang SM, Kopple KD, Koster PF, Nichols A, Peishoff CE, Samanen JM, et al.

J Med Chem. 1992 Oct 16;35(21):3970-2. No abstract available.

PMID:
1433204
36.

Inhibition of neuronally induced relaxation of canine lower esophageal sphincter by opioid peptides.

Barnette MS, Grous M, Manning CD, Callahan JF, Barone FC.

Eur J Pharmacol. 1990 Jul 3;182(2):363-8.

PMID:
2204537
37.

Passive smoking on commercial airline flights.

Mattson ME, Boyd G, Byar D, Brown C, Callahan JF, Corle D, Cullen JW, Greenblatt J, Haley NJ, Hammond K, et al.

JAMA. 1989 Feb 10;261(6):867-72.

PMID:
2913384
38.

Cyclic enkephalin analogues containing alpha-amino-beta-mercapto-beta,beta-pentamethylenepropionic acid at positions 2 or 5.

Bryan WM, Callahan JF, Codd EE, Lemieux C, Moore ML, Schiller PW, Walker RF, Huffman WF.

J Med Chem. 1989 Feb;32(2):302-4.

PMID:
2536436
39.

Structure-activity relationships of novel vasopressin antagonists containing C-terminal diaminoalkanes and (aminoalkyl)guanidines.

Callahan JF, Ashton-Shue D, Bryan HG, Bryan WM, Heckman GD, Kinter LB, McDonald JE, Moore ML, Schmidt DB, Silvestri JS, et al.

J Med Chem. 1989 Feb;32(2):391-6.

PMID:
2521519
40.

Dicarbavasopressin antagonist analogues exhibit reduced in vivo agonist activity.

Moore ML, Albrightson C, Brickson B, Bryan HG, Caldwell N, Callahan JF, Foster J, Kinter LB, Newlander KA, Schmidt DB, et al.

J Med Chem. 1988 Aug;31(8):1487-9. No abstract available.

PMID:
3397986
41.

Novel vasopressin analogues that help define a minimum effective antagonist pharmacophore.

Huffman WF, Ali FE, Bryan WM, Callahan JF, Moore ML, Silvestri JS, Yim NC, Kinter LB, McDonald JE, Ashton-Shue D, et al.

J Med Chem. 1985 Dec;28(12):1759-60. No abstract available.

PMID:
2933517
42.

Erythrocyte cholinesterase activity of domestic and laboratory animals: normal levels for nine species.

Callahan JF, Kruckenberg SM.

Am J Vet Res. 1967 Sep;28(126):1509-12. No abstract available.

PMID:
4964096
43.

CHEMICAL STRUCTURE AND SKIN PENETRATING CAPACITY OF A SHORT SERIES OF ORGANIC PHOSPHATES AND PHOSPHORIC ACID.

MARZULLI FN, CALLAHAN JF, BROWN DW.

J Invest Dermatol. 1965 May;44:339-44. No abstract available.

44.

New method of calculating yield of recipes.

CALLAHAN JF, ALDRICH PJ.

J Am Diet Assoc. 1959 Jan;35(1):45-7. No abstract available.

PMID:
13610599
45.

How to adjust recipe yields quickly and accurately.

CALLAHAN JF.

Hospitals. 1959 Jan 1;33(1):63-7. No abstract available.

PMID:
13610393
46.

The capacity of certain common laboratory animals to sweat.

MARZULLI FN, CALLAHAN JF.

J Am Vet Med Assoc. 1957 Jul 15;131(2):80-1. No abstract available.

PMID:
13438770

Supplemental Content

Loading ...
Support Center